Cargando…
Successful Treatment of Anti-Factor H Antibody-Associated Atypical Hemolytic Uremic Syndrome
Anti-complement factor H (CFH) autoantibody (Ab)-associated atypical hemolytic uremic syndrome (aHUS) has a poor prognosis in terms of frequent relapses. Although eculizumab is an effective treatment for this type of aHUS, the method of eculizumab discontinuation is not yet established. Herein, we r...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer - Medknow
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977382/ https://www.ncbi.nlm.nih.gov/pubmed/32015599 http://dx.doi.org/10.4103/ijn.IJN_336_18 |